{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:19:50Z","timestamp":1770898790386,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patient reported outcome measures (PROMs) capture impact of disease and treatment on quality of life, and have an emerging role in clinical trial outcome measurement. This study included a systematic review and quality appraisal of PROMs developed or validated for use in adults with uveitis or scleritis. We searched MEDLINE, EMBASE, PsycINFO, CINAHL and grey literature sources, to 5 November 2021. We used established quality criteria to grade each PROM instrument in multiple domains from A (high quality) to C (low quality), and assessed content development, validity, reliability and responsiveness. For instruments developed using classic test theory-based psychometric approaches, we assessed acceptability, item targeting and internal consistency. For instruments developed using Item Response Theory (IRT) (e.g. Rasch analysis), we assessed response categories, dimensionality, measurement precision, item fit statistics, differential item functioning and targeting. We identified and appraised four instruments applicable to certain uveitis types, but none for scleritis. Specifically, the National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ), a 3-part PROM for Birdshot retinochoroiditis (Birdshot Disease &amp; Medication Symptoms Questionnaire [BD&amp;MSQ], the quality of life (QoL) impact of\u00a0Birdshot Chorioretinopathy\u00a0[QoL BCR], and the QoL impact of BCR medication [QoL Meds],\u00a0the Kings Sarcoidosis Questionnaire\u00a0(KSQ), and a PROM for cytomegalovirus retinitis. These instruments had limited coverage for these heterogeneous conditions, with a focus on very rare subtypes. Psychometric appraisal revealed considerable variability between instruments, limited content development, and only one developed using Item Response Theory. In conclusion, there are few validated PROMs for patients with uveitis and none for scleritis, and existing instruments have suboptimal psychometric performance. We articulate why we do not recommend their inclusion as clinical trial outcome measures for drug licensing purposes, and highlight an unmet need for PROMs applicable to uveitis and scleritis.<\/jats:p>","DOI":"10.1186\/s12348-022-00304-3","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T13:04:55Z","timestamp":1662383095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating patient-reported outcome measures (PROMs) for clinical trials and clinical practice in adult patients with uveitis or scleritis: a systematic review"],"prefix":"10.1186","volume":"12","author":[{"given":"Charles","family":"O\u2019Donovan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Panthagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olalekan Lee","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Pesudovs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Denniston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasanee","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"304_CR1","volume-title":"Patients\u2019 Priorities and Needs for Rare Diseases Research 2014\u20132020","author":"D EOfR","year":"2011","unstructured":"EOfR D (2011) Patients\u2019 Priorities and Needs for Rare Diseases Research 2014\u20132020"},{"issue":"7","key":"304_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004905","volume":"4","author":"F Rowe","year":"2014","unstructured":"Rowe F, Wormald R, Cable R, Acton M, Bonstein K, Bowen M et al (2014) The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research prioritisation survey process. BMJ Open 4(7):e004905","journal-title":"BMJ Open"},{"issue":"12","key":"304_CR3","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/jamaneurol.2020.3502","volume":"77","author":"T Braithwaite","year":"2020","unstructured":"Braithwaite T, Subramanian A, Petzold A, Galloway J, Adderley NJ, Mollan SP et al (2020) Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. JAMA Neurol 77(12):1514\u20131523","journal-title":"JAMA Neurol"},{"issue":"2","key":"304_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD (2018) Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis 77(2):175\u2013187","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"304_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/bjophthalmol-2016-309955","volume":"101","author":"S Dean","year":"2017","unstructured":"Dean S, Mathers JM, Calvert M, Kyte DG, Conroy D, Folkard A et al (2017) \u201cThe patient is speaking\u201d: discovering the patient voice in ophthalmology. Br J Ophthalmol 101(6):700\u2013708","journal-title":"Br J Ophthalmol"},{"key":"304_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/PROM.S162802","volume":"10","author":"T Braithwaite","year":"2019","unstructured":"Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston AK (2019) The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas 10:9\u201324","journal-title":"Patient Relat Outcome Meas"},{"key":"304_CR7","unstructured":"USFaD A. Patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. : FDA; 2020 [https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical]."},{"issue":"Suppl 2","key":"304_CR8","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","volume":"10","author":"DL Patrick","year":"2007","unstructured":"Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S et al (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl 2):S125\u2013S137","journal-title":"Value Health"},{"issue":"8","key":"304_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/OPX.0000000000000001","volume":"90","author":"J Khadka","year":"2013","unstructured":"Khadka J, McAlinden C, Pesudovs K (2013) Quality assessment of ophthalmic questionnaires: review and recommendations. Optom Vis Sci 90(8):720\u2013744","journal-title":"Optom Vis Sci"},{"issue":"1","key":"304_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s41687-019-0130-5","volume":"3","author":"AM Stover","year":"2019","unstructured":"Stover AM, McLeod LD, Langer MM, Chen WH, Reeve BB (2019) State of the psychometric methods: patient-reported outcome measure development and refinement using item response theory. J Patient Rep Outcomes 3(1):50","journal-title":"J Patient Rep Outcomes"},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13023-015-0318-6","volume":"10","author":"AK Denniston","year":"2015","unstructured":"Denniston AK, Holland GN, Kidess A, Nussenblatt RB, Okada AA, Rosenbaum JT et al (2015) Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet J Rare Dis 10:97","journal-title":"Orphanet J Rare Dis"},{"key":"304_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1745-6215-15-14","volume":"15","author":"AV Ramanan","year":"2014","unstructured":"Ramanan AV, Dick AD, Benton D, Compeyrot-Lacassagne S, Dawoud D, Hardwick B et al (2014) A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials 15:14","journal-title":"Trials"},{"issue":"6","key":"304_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","volume":"135","author":"J Sheppard","year":"2017","unstructured":"Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N et al (2017) Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol 135(6):511\u2013518","journal-title":"JAMA Ophthalmol"},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41927-018-0010-2","volume":"2","author":"AV Ramanan","year":"2018","unstructured":"Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H et al (2018) A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol 2:4","journal-title":"BMC Rheumatol"},{"key":"304_CR15","volume-title":"Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial","author":"University of Bristol BTC","year":"2020","unstructured":"University of Bristol BTC (2020) Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial"},{"issue":"4","key":"304_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ajo.2009.11.019","volume":"149","author":"JH Kempen","year":"2010","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA (2010) The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 149(4):550\u201361 e10","journal-title":"Am J Ophthalmol."},{"key":"304_CR17","unstructured":"Braithwaite TL XP, J; Aiyegbusi O.L; Bayliss, S; Calvert, M; Pesudovs, K; Moore, D; Denniston, A. Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with ocular immune-mediated inflammatory diseases (uveitis, scleritis or optic neuritis): a systematic review: PROSPERO 2019 [https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019151652]."},{"key":"304_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"304_CR19","unstructured":"FaDAF UDoHaHS. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims 2009 [http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf ]."},{"issue":"7","key":"304_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","volume":"63","author":"LB Mokkink","year":"2010","unstructured":"Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63(7):737\u2013745","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"304_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11136-010-9606-8","volume":"19","author":"LB Mokkink","year":"2010","unstructured":"Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL et al (2010) The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res 19(4):539\u2013549","journal-title":"Qual Life Res"},{"issue":"4","key":"304_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.survophthal.2016.12.011","volume":"62","author":"M Prem Senthil","year":"2017","unstructured":"Prem Senthil M, Khadka J, Pesudovs K (2017) Assessment of patient-reported outcomes in retinal diseases: a systematic review. Surv Ophthalmol 62(4):546\u2013582","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"304_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/OPX.0b013e318141fe75","volume":"84","author":"K Pesudovs","year":"2007","unstructured":"Pesudovs K, Burr JM, Harley C, Elliott DB (2007) The development, assessment, and selection of questionnaires. Optom Vis Sci 84(8):663\u2013674","journal-title":"Optom Vis Sci"},{"issue":"3","key":"304_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jcrs.2008.11.038","volume":"35","author":"M Lundstrom","year":"2009","unstructured":"Lundstrom M, Pesudovs K (2009) Catquest-9SF patient outcomes questionnaire: nine-item short-form Rasch-scaled revision of the Catquest questionnaire. J Cataract Refract Surg 35(3):504\u2013513","journal-title":"J Cataract Refract Surg"},{"issue":"12","key":"304_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/OPX.0000000000001143","volume":"94","author":"H Kandel","year":"2017","unstructured":"Kandel H, Khadka J, Goggin M, Pesudovs K (2017) Patient-reported Outcomes for Assessment of Quality of Life in Refractive Error: A Systematic Review. Optom Vis Sci 94(12):1102\u20131119","journal-title":"Optom Vis Sci"},{"issue":"6","key":"304_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3928\/1081597X-20170310-01","volume":"33","author":"H Kandel","year":"2017","unstructured":"Kandel H, Khadka J, Lundstrom M, Goggin M, Pesudovs K (2017) Questionnaires for Measuring Refractive Surgery Outcomes. J Refract Surg 33(6):416\u2013424","journal-title":"J Refract Surg"},{"issue":"4","key":"304_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cxo.12553","volume":"101","author":"SE Kumaran","year":"2018","unstructured":"Kumaran SE, Khadka J, Baker R, Pesudovs K (2018) Patient-reported outcome measures in amblyopia and strabismus: a systematic review. Clin Exp Optom 101(4):460\u2013484","journal-title":"Clin Exp Optom"},{"issue":"3","key":"304_CR28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/ICO.0000000000002170","volume":"39","author":"H Kandel","year":"2020","unstructured":"Kandel H, Pesudovs K, Watson SL (2020) Measurement of Quality of Life in Keratoconus. Cornea 39(3):386\u2013393","journal-title":"Cornea"},{"issue":"10","key":"304_CR29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1177\/1049732318821692","volume":"29","author":"MM Hennink","year":"2019","unstructured":"Hennink MM, Kaiser BN, Weber MB (2019) What Influences Saturation? Estimating Sample Sizes in Focus Group Research. Qual Health Res 29(10):1483\u20131496","journal-title":"Qual Health Res"},{"issue":"5","key":"304_CR30","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","volume":"27","author":"LB Mokkink","year":"2018","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM et al (2018) COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life Res 27(5):1171\u20131179","journal-title":"Qual Life Res"},{"issue":"7","key":"304_CR31","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.ophtha.2014.01.007","volume":"121","author":"JA Barry","year":"2014","unstructured":"Barry JA, Folkard A, Denniston AK, Moran E, Ayliffe W (2014) Development and validation of quality-of-life questionnaires for birdshot chorioretinopathy. Ophthalmology. 121(7):1488\u20139 e2","journal-title":"Ophthalmology."},{"issue":"7","key":"304_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archopht.1996.01100140055008","volume":"114","author":"AW Wu","year":"1996","unstructured":"Wu AW, Coleson LC, Holbrook J, Jabs DA (1996) Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group. Arch Ophthalmol. 114(7):841\u20137","journal-title":"Arch Ophthalmol."},{"issue":"4","key":"304_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0895-4356(00)00294-8","volume":"54","author":"BK Martin","year":"2001","unstructured":"Martin BK, Kaplan Gilpin AM, Jabs DA, Wu AW (2001) Studies of Ocular Complications of ARG. Reliability, validity, and responsiveness of general and disease-specific quality of life measures in a clinical trial for cytomegalovirus retinitis. J Clin Epidemiol. 54(4):376\u201386","journal-title":"J Clin Epidemiol."},{"issue":"1","key":"304_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","volume":"68","author":"AS Patel","year":"2013","unstructured":"Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA et al (2013) The development and validation of the King\u2019s Sarcoidosis Questionnaire for the assessment of health status. Thorax 68(1):57\u201365","journal-title":"Thorax"},{"issue":"7","key":"304_CR35","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD et al (2001) Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119(7):1050\u20131058","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"304_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/2013.jamaophthalmol.102","volume":"131","author":"RK Naik","year":"2013","unstructured":"Naik RK, Rentz AM, Foster CS, Lightman S, Belfort R Jr, Lowder C et al (2013) Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol 131(2):219\u2013225","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"304_CR37","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s11136-013-0412-y","volume":"22","author":"RK Naik","year":"2013","unstructured":"Naik RK, Gries KS, Rentz AM, Kowalski JW, Revicki DA (2013) Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis. Qual Life Res 22(10):2801\u20132808","journal-title":"Qual Life Res"},{"issue":"2","key":"304_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/archopht.116.2.227","volume":"116","author":"CM Mangione","year":"1998","unstructured":"Mangione CM, Berry S, Spritzer K, Janz NK, Klein R, Owsley C et al (1998) Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol 116(2):227\u2013233","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"304_CR39","first-page":"1496","volume":"116","author":"CM Mangione","year":"1998","unstructured":"Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD (1998) Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators Arch Ophthalmol 116(11):1496\u20131504","journal-title":"NEI-VFQ Field Test Investigators Arch Ophthalmol"},{"issue":"5","key":"304_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archopht.1994.01090170074026","volume":"112","author":"EP Steinberg","year":"1994","unstructured":"Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD et al (1994) The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol. 112(5):630\u20138","journal-title":"Arch Ophthalmol."},{"issue":"7","key":"304_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00005650-198807000-00007","volume":"26","author":"AL Stewart","year":"1988","unstructured":"Stewart AL, Hays RD, Ware JE Jr (1988) The MOS short-form general health survey Reliability and validity in a patient population. Med Care. 26(7):724\u201335","journal-title":"Med Care."},{"issue":"6","key":"304_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 30(6):473\u201383","journal-title":"Med Care."},{"issue":"1","key":"304_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jval.2014.10.005","volume":"18","author":"J Petrillo","year":"2015","unstructured":"Petrillo J, Cano SJ, McLeod LD, Coon CD (2015) Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. Value Health 18(1):25\u201334","journal-title":"Value Health"},{"key":"304_CR44","first-page":"159","volume":"24","author":"JHK Devine","year":"2015","unstructured":"Devine JHK, Skup M, Chao J, Ganguli A, Sheppard J (2015) Establishing content validity for the National Eye Institute\u2019s Visual Function Questionnaire (VFQ-25) in intermediate, posterior, and panuveitis. Qual Life Res 24:159","journal-title":"Qual Life Res"},{"issue":"4","key":"304_CR45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1167\/iovs.02-0292","volume":"44","author":"D Globe","year":"2003","unstructured":"Globe D, Varma R, Azen SP, Paz S, Yu E, Preston-Martin S et al (2003) Psychometric performance of the NEI VFQ-25 in visually normal Latinos: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 44(4):1470\u20131478","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"304_CR46","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1167\/iovs.08-3225","volume":"50","author":"IJ Suner","year":"2009","unstructured":"Suner IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM (2009) Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 50(8):3629\u20133635","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"304_CR47","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1167\/iovs.09-4494","volume":"51","author":"M Marella","year":"2010","unstructured":"Marella M, Pesudovs K, Keeffe JE, O\u2019Connor PM, Rees G, Lamoureux EL (2010) The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 51(6):2878\u20132884","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"304_CR48","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jcrs.2009.11.019","volume":"36","author":"K Pesudovs","year":"2010","unstructured":"Pesudovs K, Gothwal VK, Wright T, Lamoureux EL (2010) Remediating serious flaws in the National Eye Institute Visual Function Questionnaire. J Cataract Refract Surg 36(5):718\u2013732","journal-title":"J Cataract Refract Surg"},{"key":"304_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-7525-11-10","volume":"11","author":"AJ Lloyd","year":"2013","unstructured":"Lloyd AJ, Loftus J, Turner M, Lai G, Pleil A (2013) Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health Qual Life Outcomes 11:10","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"304_CR50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12955-017-0726-5","volume":"15","author":"J Petrillo","year":"2017","unstructured":"Petrillo J, Bressler NM, Lamoureux E, Ferreira A, Cano S (2017) Development of a new Rasch-based scoring algorithm for the National Eye Institute Visual Functioning Questionnaire to improve its interpretability. Health Qual Life Outcomes 15(1):157","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"304_CR51","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41433-019-0481-4","volume":"33","author":"T Braithwaite","year":"2019","unstructured":"Braithwaite T, Davis N, Galloway J (2019) Cochrane corner: why we still don\u2019t know whether anti-TNF biologic therapies impact uveitic macular oedema. Eye (Lond) 33(12):1830\u20131832","journal-title":"Eye (Lond)"},{"issue":"9","key":"304_CR52","doi-asserted-by":"publisher","first-page":"e011142","DOI":"10.1136\/bmjopen-2016-011142","volume":"6","author":"P Moore","year":"2016","unstructured":"Moore P, Jackson C, Mutch K, Methley A, Pollard C, Hamid S et al (2016) Patient-reported outcome measure for neuromyelitis optica: pretesting of preliminary instrument and protocol for further development in accordance with international guidelines. BMJ Open 6(9):e011142","journal-title":"BMJ Open"},{"issue":"12","key":"304_CR53","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/OPX.0000000000000992","volume":"93","author":"J Khadka","year":"2016","unstructured":"Khadka J, Fenwick E, Lamoureux E, Pesudovs K (2016) Methods to Develop the Eye-tem Bank to Measure Ophthalmic Quality of Life. Optom Vis Sci 93(12):1485\u20131494","journal-title":"Optom Vis Sci"},{"issue":"7","key":"304_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.9.7.3","volume":"9","author":"EK Fenwick","year":"2020","unstructured":"Fenwick EK, Barnard J, Gan A, Loe BS, Khadka J, Pesudovs K et al (2020) Computerized Adaptive Tests: Efficient and Precise Assessment of the Patient-Centered Impact of Diabetic Retinopathy. Transl Vis Sci Technol 9(7):3","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"304_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J et al (2018) Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis 13(1):61","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"304_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MLR.0000000000000289","volume":"53","author":"RE Jensen","year":"2015","unstructured":"Jensen RE, Rothrock NE, DeWitt EM, Spiegel B, Tucker CA, Crane HM et al (2015) The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care 53(2):153\u2013159","journal-title":"Med Care"},{"issue":"14","key":"304_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMp1707537","volume":"377","author":"LS Rotenstein","year":"2017","unstructured":"Rotenstein LS, Huckman RS, Wagle NW (2017) Making Patients and Doctors Happier - The Potential of Patient-Reported Outcomes. N Engl J Med 377(14):1309\u20131312","journal-title":"N Engl J Med"},{"key":"304_CR58","unstructured":"FD A. Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making 2020 [https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical]."},{"issue":"1","key":"304_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11136-020-02625-z","volume":"30","author":"NL Crossnohere","year":"2021","unstructured":"Crossnohere NL, Brundage M, Calvert MJ, King M, Reeve BB, Thorner E et al (2021) International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Qual Life Res 30(1):21\u201340","journal-title":"Qual Life Res"},{"issue":"5","key":"304_CR60","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT et al (2018) Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA 319(5):483\u2013494","journal-title":"JAMA"},{"key":"304_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1477-7525-11-184","volume":"11","author":"M Calvert","year":"2013","unstructured":"Calvert M, Brundage M, Jacobsen PB, Schunemann HJ, Efficace F (2013) The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 11:184","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"304_CR62","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L (2017) Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report. Value Health 20(7):838\u2013855","journal-title":"Value Health"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-022-00304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-022-00304-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-022-00304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T14:05:55Z","timestamp":1662386755000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-022-00304-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1186\/s12348-022-00304-3","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}